Margaret K. Callahan
Memorial Sloan Kettering Cancer Center · 426 works · 51,027 citations · h-index 68
Top works
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- Nivolumab plus Ipilimumab in Advanced Melanoma
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- Immune Checkpoint Blockade in Cancer Therapy
- Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
- Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
- OncoKB: A Precision Oncology Knowledge Base
- Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
- Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy
- Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody
- Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer
- Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL).
- Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial
- Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
- Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
- Immune-related adverse events of checkpoint inhibitors
- Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution
- Hepatotoxicity with Combination of Vemurafenib and Ipilimumab
- Immune Modulation in Cancer with Antibodies
- Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo